International Congress of Parkinson’s Disease and Movement Disorders ® 2022
Oxford University Innovation's Clinical Outcome team will be attending the annual MDS 2022 conference in Madrid, Spain from the 15th - 18th September 2022.
FDA approves Myfembree® for endometriosis pain management
Impact of pain on daily activities measured by the Endometriosis Health Profile-30 (EHP-30) during Clinical Trials.
Clinical Outcomes are proud to be sponsoring the PROMs Research Conference 2022
Only one week to go! The Annual PROMs Research Conference, hosted by the Welsh Value in Healthcare Center, will be taking place online Tuesday 14th and Wednesday 15th June 2022.
The Society of Tissue Viability Conference 2022 – Solving skin and wound challenges together
Dr Rhiannon Macefield will be presenting the Bluebelle Wound Healing Questionnaire at this year's Society of Tissue Viability Conference.
What is your postop patient recovery / monitoring requirement and which scale best fits that need?
The Clinical Outcomes team at Oxford University Innovation have brought together a portfolio of COA instruments to tackle the need of effectively monitoring or measuring various aspects of post-surgical recovery and outcomes.
ISPOR 2022
Oxford University Innovation's Clinical Outcome team will be attending the annual ISPOR 2022 conference in Washington, DC, USA from the 15th - 18th May 2022.
PDQ-39 used to evaluate Health-Related Quality of Life in randomized controlled trial that uses DBS system to treat patients with Parkinson’s disease
Patients were implanted bilaterally with Boston Scientific’s FDA-approved Vercise Genus DBS system. During long-term follow-up, quality of life was evaluated using the Parkinson’s Disease Questionnaire (PDQ-39).
© Oxford University Innovation